Investor Presentaiton
LPA₁
Sotyktu
CD19 NEX T
Immunology
Significant unmet need in pulmonary fibrosis
Disease
• Fibrotic ILD: Associated with
thickening of the lung lining,
causing irreversible damage¹
•
IPF: Fatal disease with 3-5 years
median survival²
PPF: Heterogenous group of ILDS
with a progressive-fibrosing
phenotype¹
•
Unmet Need
Ideal novel therapies which can
be used alone or in combination
with approved anti-fibrotics
• Treatments needed to address
underlying fibrosis and reduce
decline in lung function
⚫ Tolerable treatment options to
increase adherence and QoL
improvement
.
Treatment Opportunity
Deliver a potential new product
with an improved efficacy and
tolerability profile over current
treatment options
Approved therapies do not treat
underlying fibrosis or halt disease
progression
1. Raghu. Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. 2. Raghu. Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824.
Bristol Myers Squibb™
Not for Product Promotional Use
57View entire presentation